Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022
Posted on 27 Jul 2022
Meridian Bioscience Inc. (Cincinnati, OH, USA) is attending the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo where the company will exhibit its state-of-the-art urea breath test system alongside its advanced fluorescent immunoassay and molecular platforms.
At AACC 2022, Meridian will display its state-of-the-art BreathID Hp Lab urea breath test system for H. pylori detection that intuitively combines market-leading diagnostic accuracy with efficient automation and fast batch-test analysis for maximizing large lab testing throughput. The system’s built-in automated monitoring manages batch analysis, moving from test sample to test sample while noting any sample errors for post-batch handling. The BreathID platform can be used in conjunction with other Meridian H. pylori platforms for a total testing solution across the health system.
Meridian is also exhibiting the Curian fluorescent immunoassay platform focused on gastrointestinal testing that is packaged in a small footprint to improve hospital operational efficiencies. Curian provides healthcare systems a rapid fluorescent immunoassay diagnostic solution with a standardized, simplified workflow that eliminates subjectivity. Laboratories can eliminate workflow burdens and achieve optimal efficiency while delivering top-of-the-line patient care.
Also on display at Meridian’s booth will be the company’s Revogene flexible molecular platform capable of single analyte and multiplex testing that is packaged in a small footprint, and can help standardize testing throughout the health system. Revogene is a fully automated molecular platform that features single and multiplex testing capabilities with minimal hands-on time. The flexible, scalable platform comes with a broad test menu for the detection of hospital inquired infections, gastrointestinal, respiratory, and neonatal diseases.
Related Links:
Meridian Bioscience Inc.
